‘Revolutionary Human Stem Cell Trial’ Featured as Part of ‘2013 Smart Guide’
MARLBOROUGH, Mass. — Dec. 20, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has been named as one of the “10 Ideas That Will Shape The Year” in the ‘Christmas and New Year Special’ issue of the New Scientist, widely considered to be one of the most influential science and technology news magazines in the world.
The list includes innovations in different scientific areas such as health and medicine, climate change, technology and others. ACT’s platelet program aims to provide a renewable, donorless source of blood platelets to people in need of platelet transfusions.
“Human iPS cells are a game-changer in medicine,” said Robert Lanza, M.D., chief scientific officer of ACT. “They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets don’t contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013.”
ACT plans to compare normal and iPS cell-derived platelets in eight healthy volunteers and analyze recovery and survival. Additionally, normal platelets will be compared to human embryonic stem cell-derived platelet cells.
“We appreciate this recognition from the New Scientist,” commended Gary Rabin, chairman and CEO. “It speaks to the growing importance of the stem cell and regenerative medicine sector.”
Link to Article in New Scientist:
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
CEOcast, Inc., James Young, 212-732-4300
ACT Corporate Communications, Bill Douglass, 646-450-3615
Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292